Assessing the Cost Effectiveness of an Incremental Lipid‐Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data | Synapse
April 10, 2026Open Access
Assessing the Cost Effectiveness of an Incremental Lipid‐Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data
Key Points
This analysis aims to evaluate the cost effectiveness of an incremental lipid-lowering therapy approach after coronary artery bypass grafting using nationwide data.
Simulated stepwise lipid-lowering therapy
Used high-intensity statins and ezetimibe
Assessed cost outcomes at various willingness-to-pay thresholds
Few patients required bempedoic acid or PCSK9 inhibitors
The approach was cost-effective at very low willingness-to-pay thresholds
Abstract
Few patients needed bempedoic acid or PCSK9is when simulating stepwise LLT with high-intensity statins and ezetimibe. Such an approach was observed as cost effective at very low willingness-to-pay thresholds.